Green tea intake and its effect on laboratory parameters and disease symptoms in hospitalised patients with Covid 19: a structured protocol for a randomized controlled trial

AbstractObjectivesThe current randomized controlled trial (RCT) will be conducted to assess the effect of green tea intake on disease symptoms and laboratory parameters including C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and complete blood count (CBC) in patients with mild-to-moderate Covid-19 infection.Trial designRandomized, double-blinded, parallel (1:1 ratio) clinical trial exploratory studyParticipantsWe will recruit patients with COVID-19 infection admitted to Yasuj Shahid Jalil Hospital in Yasuj City, Kohgiluyeh and Boyer-Ahmad Province, Iran.Participants ’ inclusion criteria are as follows:Inclusion CriteriaPatients aged ≥18 yearsCOVID-19 diagnosis according to real-time polymerase chain reaction (RT-PCR)Exclusion CriteriaPregnancy or lactationDisseminated intravascular coagulation or any other types of coagulopathySevere congestive kidney failureHaving a history of participating in a clinical trial during the last 30 daysIntervention and comparatorIntervention: Two capsules containing 450 mg green tea extract along with routine treatment for COVID-19 patients in the intervention group. Two capsules containing placebo plus routine treatment for patients with COVID-19 infection. Capsules will be taken twice a day, after lunch and dinner, for 14 days.Main outcomesChanges in disease symptoms and laboratory parameters including CRP, ESR, and CBC after 14 days of the intervention compared to control group.RandomisationEligible patients will be ran...
Source: Trials - Category: Research Source Type: clinical trials